Business
The Government of Malawi & TNI Biotech sign agreement to open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital
The Government of Malawi & TNI Biotech sign agreement to open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital.
About this update from Biostax Corp.
[{"type":"text","content":" 0 0 1 835 4766 Brinen & Associates, LLC 39 11 5590 14.0 544x376 Normal 0 false false false EN-US JA X-NONE The Government of Malawi & TNI Biotech Sign Agreement to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital NEW YORK, NY-- (September 25, 2012) - Her Excellency, Mrs. Joyce Banda, the President of the Republic of Malawi, announced today that an agreement has been reached to open an outpatient clinic at Queen Elizabeth Central Hospital for the treatment of cancer and infectious diseases with US-based biotech firms TNI BioTech, Inc. [PINKSHEETS: TNIB] (TNIB) and GB Oncology & Imaging Group LLC (GBOIG).The World Health Organization estimates that chronic infectious diseases cause more than 20 percent of all cancers in the world, including liver, cervical and gastric malignancies. Infection-related cancers are more frequent and often more severe in people infected with HIV. Cancer patients in Malawi have had abysmal survival rates due to lack of access to early diagnosis and treatment. President Mrs. Joyce Banda, a long time advocate for women’s rights in the areas of health, education and gender equality continues her fight to provide adequate access to effective treatment for cancer and infectious diseases in Malawi; today cancer is almost a death sentence due to a lack of care. President Banda has taken the first step in reversing this problem by signing an agreement with TNIB and GBOIG to open an outpatient clinic for the treatment of cancer, HIV/AIDS and infectious diseases at Queen Elizabeth Central Hospital within the coming months. At the clinic TNIB and GBOIG will deliver both conventional and alternative therapies; including safer, more effective cancer therapies, new-targeted drug therapies and minimally invasive surgical alternatives. Some of the leaders inthe field of immunology and oncology have joined TNIB and GBOIG in their endeavor such as Dr. Ronald Herberman, TNIB’s Chief Medical Officer and the founding director of the University of Pittsburgh Cancer Institute (UPCI) as well as the UPMC Cancer Center. Advisory Board Member, Dr. Dalgleish was appointed Foundation Chair of Oncology at St. George’s University of London in 1991. Dr. Ndiouga Dieng, a graduate from Howard University, holds the position of Senior Pharmacy Ma...